About
Carlos Loya is a scientist and biotech executive who served as a founding team member at SAGE Therapeutics and Praxis Precision Medicines, where he contributed to the strategy, discovery, and development of multiple programs including Zulresso™ and Zurzuvae™, both of which received FDA approval. His expertise spans neuroscience and RNA biology, with professional experience in corporate development, licensing, partnerships, drug discovery strategy, and capital raising.
Experience
- 82VSVenture Partner2024 — 2026Greater Boston
- 82VSExecutive In Residence2021 — 2024Cambridge, Massachusetts, United States
- Aldebaran TherapeuticsFounder & Board Member2022 — 2026Greater Boston
- Alloy Therapeutics, Inc.Head of Partnering | Genetic Medicines2024 — 2025Greater Boston
- Praxis Precision Medicines, Inc.Global Commercial Lead2020 — 2021Cambridge, Massachusetts, United States
- Praxis Precision Medicines, Inc.Director of Corporate Development2018 — 2021Cambridge, Massachusetts, United States
- Collegium Pharmaceutical, Inc.Associate Director of Corporate Development2016 — 2018Greater Boston
- inVentiv Health - Campbell AllianceEngagement Manager, Corporate Development & Strategy Practice2014 — 2016Greater Boston
- Sage TherapeuticsDrug Discovery and Porfolio Strategy2011 — 2014Cambridge, MA
- Third Rock VenturesConsultant2011Boston, MA
- Harvard Medical SchoolKirschstein & Ryan Graduate Research Fellow2005 — 2011Greater Boston
- Siemens Venture CapitalBusiness Analyst Intern2010Greater Boston
Education
- Harvard Medical SchoolPhD, Neurobiology
- New Mexico State UniversityBS, Biochemistry
- University of Lausanne - UNILBS, Biochemistry and French
Skills & more
Lifesciences31Biotechnology39Genetics20Neuroscience23Biochemistry15Entrepreneurship12Genomics9Drug Discovery20Genetic EngineeringMarket Analysis4Venture Capital2RNAi
+12 more
BiopharmaceuticalsLife SciencesCell CultureCommercializationPharmacologyMolecular BiologyPharmaceutical IndustryClinical DevelopmentStrategyNegotiationBusiness DevelopmentFinanceLanguages English · French · Spanish
From Carlos's professional profile.
Same school
Also attended Harvard Medical School113
Niko BonatsosInvestment Team at General CatalystAnthony PhilippakisInvestor at GV (Google Ventures)Ben RobbinsInvestor at GV (Google Ventures)David ReshefInvestor at GV (Google Ventures)Krishna YeshwantInvestor at GV (Google Ventures)Morgan CheathamPartner and Head of Healthcare and Life Sciences at Breyer Capital
+ 107 more
Also attended New Mexico State University5
Also attended University of Lausanne - UNIL14
Lorenzo LeoniFounder and Managing Director at Ti-VenturesPascal H. WidmerPartner at Alpana VenturesAlexander LangeFounding GP at Inflection.xyzImed KhammariChief Risk Officer at Arab Bank (Switzerland)Ulrika KoppInvestment Manager at ProcuritasIván BustosPortfolio Analyst at Rockstart
+ 8 more
Shared employers
Also worked at Alloy Therapeutics, Inc.19
Jesse RobbinsFounder and Investor in AI Developer ToolsChaya PatelPrincipal at Mission BiocapitalAlasdair ThongFounding Partner at Selvedge VentureEsra BerkolChief of Staff at Selvedge VentureMike SchmidtGeneral Partner, President and Head of 82VS Boston at 82VSVic StoneGeneral Partner, President and Head of 82VS Dallas at 82VS
+ 13 more
Also worked at inVentiv Health - Campbell Alliance3
Also worked at Sage Therapeutics4
Also worked at Third Rock Ventures81
Lisa PurcellInvestor at Third Rock VenturesPaul MeloneInvestor at Third Rock VenturesLee VeneziaInvestor at Third Rock VenturesKevin MunnellyInvestor at Third Rock VenturesAmanda ChanInvestor at Third Rock VenturesJigar RaythathaInvestor at Third Rock Ventures
+ 75 more
Colleagues at 82VS
Andrei Ramirez-Valdez
Venture Associate at 82VS
Andrew Peterson
Founder / EIR at 82VS
Arthur Suckow
Investor at 82VS
Caitlin Tolman
Chief Operating Officer at 82VS
Colby Jordan
Vice President, Capital Formation at 82VS
Dongxing Zha
Founder / EIR at 82VS
Errik Anderson
General Partner at 82VS
Hemanta Baruah
Founder / EIR at 82VS

.png)



















.png)

















